

ZEMETHIS 15 | 30 | 60 | 120 MG

Soft Chews

Antiemetic Neurokinin-1 (NK-1) Receptor Antagonist



Formulation

Each chewable tablet contains: Zemethis® 15 mg: Maropitant (as maropitant citrate) 15 mg. Zemethis® 30 mg: Maropitant (as maropitant citrate) 30 mg. Zemethis® 60 mg: Maropitant (as maropitant citrate) 60 mg. Zemethis® 120 mg: Maropitant (as maropitant citrate) 120 mg.

Indications

Prevention and treatment of acute vomiting. Prevention of vomiting, including those induced by motion sickness (travel sickness), Prevention and treatment of vomiting and nausea in dogs undergoing multiagent chemotherapy, Maropitant tablets are indicated for the prevention of acute vomiting in dogs from 2 months of age and vomiting due to motion sickness in dogs from 4 months of age.

Dosage and Administration

Oral route. Prevention of motion sickness: 8 mg/kg (the tablet can be split for greater dosage accuracy). Zemethis® 15 mg: Chemotherapy-related vomiting and other vomiting: Minimum dose of 2 mg/kg (1 tablet for dogs weighing 3.75–7.5 kg). Zemethis® 30 mg: Chemotherapy-related vomiting and other vomiting: Minimum dose of 2 mg/kg (1 tablet for dogs weighing 7.5–15 kg). Zemethis® 60 mg: Chemotherapy-related vomiting and other vomiting: Minimum dose of 2 mg/kg (1 tablet for dogs weighing 15–30 kg). Zemethis® 120 mg: Chemotherapy-related vomiting and other vomiting: Minimum dose of 2 mg/kg (1 tablet for dogs weighing 30–60 kg).

Commercial Presentation

Box of 1 or 4 soft chewable tablets in sealed aluminum blister pack of 1 g., Box of 1 or 4 soft chewable tablets in sealed aluminum blister pack of 2 g.,

SENASA Registry

F.043.031.000026, es una referencia informativa y no debe ser considerado como recomendaciones de uso.